Donanemab has shown positive results in a Phase 3 clinical trial called TRAILBLAZER-ALZ 2. The study evaluated the safety and effectiveness of the drug that targets amyloid plaques in people with early symptomatic Alzheimer’s disease.
Read more about Donanemab’s performance here.